Dedicated to making a world of difference in cancer care, the American Society of Clinical Oncology and its affiliated organization, the American Association of Clinical Oncology (ASCO), laud the goals, progress, and continued potential of the Cancer Moonshot initiative. Having the full support of the President and the resources of the federal government is essential to our shared goal of accelerating the pace of progress against a disease that will be diagnosed in more than 1.9 million people in the U.S. this year.

One June 8, CancerLinQ^® LLC and HealthVerity, Inc., today announced a collaboration that will create the nation’s premier real-world oncology data ecosystem to advance cancer care and research for government and public health agencies. 

Boston and Alexandria, VA – ASCO’s CancerLinQ® and Count Me In announced today a new collaboration that aims to allow cancer researchers to learn from every patient with cancer, by actively engaging patients as part of the clinical research enterprise. CancerLinQ – a real world oncology data technology platform developed by the American Society of Clinical Oncology (ASCO) – collects and aggregates de-identified EHR data from oncology practices across the United States to advance cancer care through quality improvement and research. Count Me In, a non-profit research initiative of the Broad Institute of MIT and Harvard, the Emerson Collective, and Dana-Farber Cancer Institute, provides patients with a mechanism to participate in cancer research by sharing their unique, de-identified medical information and history with cancer researchers and investigators.

Sean Khozin, MD, MPH, has been named Chief Executive Officer of CancerLinQ LLC, and he will begin his new role overseeing the continued expansion and implementation of CancerLinQ, ASCO’s real-world oncology data platform designed to improve the quality of care for people with cancer and drive new research, on February 16. 

On May 29, ASCO’s CancerLinQ® announced that it launched a new platform for CancerLinQ Discovery®, its de-identified real-world cancer data product for researchers across the cancer community. 

Two science-based organizations—CancerLinQ LLC, a nonprofit subsidiary of the American Society of Clinical Oncology, and the American Heart Association, the leading voluntary health organization devoted to a world of longer, healthier lives—are teaming up to make oncology datasets from the CancerLinQ Discovery® database available to academic researchers, non-profits, health care providers and government agencies through a customized version of the American Heart Association’s Precision Medicine Platform.

Chicago — In an effort to advance cancer data sharing and improve the quality and coordination of patient care, three of the nation’s leading health and technology organizations have established a core set of data elements and recommended technical specifications (the Minimal Common Oncology Data Elements, or “mCODE”) that are essential for capturing and reporting the characteristics, treatments, and outcomes of every cancer patient and should be contained in each patient’s electronic health record (EHR). The mCODE™ initiative, a collaboration between the American Society of Clinical Oncology, Inc. (ASCO®), its wholly owned nonprofit subsidiary CancerLinQ LLC, the MITRE Corporation, and the Alliance for Clinical Trials in Oncology Foundation (Alliance Foundation), released the initial set of common cancer data standards and specifications today at ASCO’s 2019 Annual Meeting in Chicago and published them online at mCODEinitiative.org.